3 results on '"Faustini, Sian E"'
Search Results
2. SARS‐CoV‐2‐specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi‐System Syndrome
- Author
-
Perez‐toledo, Marisol, Faustini, Sian E., Jossi, Sian E., Shields, Adrian M., Marcial‐juarez, Edith, Kanthimathinathan, Hari Krishnan, Allen, Joel D., Watanabe, Yasunori, Goodall, Margaret, Willcox, Benjamin E., Willcox, Carrie R., Salim, Mahboob, Wraith, David C., Veenith, Tonny V., Syrimi, Eleni, Drayson, Mark T., Jyothish, Deepthi, Al‐abadi, Eslam, Chikermane, Ashish, Welch, Steven B., Masilamani, Kavitha, Hackett, Scott, Crispin, Max, Scholefield, Barnaby R., Cunningham, Adam F., Richter, Alex G., and Genuneit, Jon
- Subjects
2019-20 coronavirus outbreak ,biology ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,medicine.disease ,Virology ,Immunoglobulin G ,Systemic inflammatory response syndrome ,Immunoglobulin M ,Pediatrics, Perinatology and Child Health ,biology.protein ,Immunology and Allergy ,Medicine ,business ,Letters to the Editor ,Letter to the Editor - Abstract
During the COVID-19 outbreak, reports have surfaced of children who present with features of a multisystem inflammatory syndrome with overlapping features of Kawasaki disease and toxic shock syndrome - Paediatric Inflammatory Multisystem Syndrome- temporally associated with SARS-CoV-2 pandemic (PIMS-TS). Initial reports find that many of the children are PCR-negative for SARS-CoV-2, so it is difficult to confirm whether this syndrome is a late complication of viral infection in an age group largely spared the worst consequences of this infection, or if this syndrome reflects enhanced surveillance.Children hospitalised for symptoms consistent with PIMS-TS between 28 April and 8 May 2020, and who were PCR-negative for SARS-CoV-2, were tested for antibodies to viral spike glycoprotein using an ELISA test.Eight patients (age range 7-14 years, 63% male) fulfilled case-definition for PIMS-TS during the study period. Six of the eight patients required admission to intensive care. All patients exhibited significant IgG and IgA responses to viral spike glycoprotein. Further assessment showed that the IgG isotypes detected in children with PIMS-TS were of the IgG1 and IgG3 subclasses, a distribution similar to that observed in samples from hospitalised adult COVID-19 patients. In contrast, IgG2 and IgG4 were not detected in children or adults. IgM was not detected in children, which contrasts with adult hospitalised adult COVID-19 patients of whom all had positive IgM responses.Strong IgG antibody responses can be detected in PCR-negative children with PIMS-TS. The low detection rate of IgM in these patients is consistent with infection having occurred weeks previously and that the syndrome onset occurs well after the control of SARS-CoV-2 viral load. This implies that the disease is largely immune-mediated. Lastly, this indicates that serology can be an appropriate diagnostic tool in select patient groups.
- Published
- 2021
3. Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine
- Author
-
Herbert, Jenny A, Kay, Emily J, Faustini, Sian E, Richter, Alex, Abouelhadid, Sherif, Cuccui, Jon, Wren, Brendan, and Mitchell, Timothy J
- Subjects
Vaccines, Synthetic/administration & dosage ,Glycoengineering ,Polysaccharides, Bacterial/immunology ,Article ,Pneumococcal Vaccines ,Mice ,Conjugate vaccine ,Escherichia coli ,Animals ,Technology, Pharmaceutical ,Pneumococcal Vaccines/administration & dosage ,Streptococcus pneumoniae/immunology ,Pneumonia, Pneumococcal/immunology ,Vaccines, Synthetic ,Vaccines, Conjugate ,Protein glycan coupling technology ,Polysaccharides, Bacterial ,Pneumonia ,Pneumonia, Pneumococcal ,Vaccines, Conjugate/administration & dosage ,Escherichia coli/genetics ,Disease Models, Animal ,Streptococcus pneumoniae ,Treatment Outcome ,Technology, Pharmaceutical/economics ,Female - Abstract
Highlights • Pneumococcal glycoconjugate vaccines produced in E. coli are protective in mice. • Protection correlates with opsonic antibody levels. • This is a cheaper way to produce conjugate vaccines., Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Although this is a vaccine preventable disease, S. pneumoniae still causes over 1 million deaths per year, mainly in children under the age of five. The biggest disease burden is in the developing world, which is mainly due to unavailability of vaccines due to their high costs. Protein polysaccharide conjugate vaccines are given routinely in the developed world to children to induce a protective antibody response against S. pneumoniae. One of these vaccines is Prevnar13, which targets 13 of the 95 known capsular types. Current vaccine production requires growth of large amounts of the 13 serotypes, and isolation of the capsular polysaccharide that is then chemically coupled to a protein, such as the diphtheria toxoid CRM197, in a multistep expensive procedure. In this study, we design, purify and produce novel recombinant pneumococcal protein polysaccharide conjugate vaccines in Escherichia coli, which act as mini factories for the low-cost production of conjugate vaccines. Recombinant vaccine efficacy was tested in a murine model of pneumococcal pneumonia; ability to protect against invasive disease was compared to that of Prevnar13. This study provides the first proof of principle that protein polysaccharide conjugate vaccines produced in E. coli can be used to prevent pneumococcal infection. Vaccines produced in this manner may provide a low-cost alternative to the current vaccine production methodology.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.